Physician profile
Parminder Kaur Janda
NPI 1912994237
$4,084.93
in general payments reported to CMS, 2019-2025
29 companies · $427 in 2025
The $427 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $903 · 2020: $443 · 2021: $1,047 · 2022: $652 · 2023: $219 · 2024: $393 · 2025: $427.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,039.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,039.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $624.14 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Amgen INC. | $579.48 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $385.06 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $370.59 | 2019-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $283.09 | 2021-2024 | |
| Lilly USA, LLC | $217.31 | 2019-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $206.52 | 2019-2021 | |
| Pfizer INC. | $203.19 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $157.08 | 2021 | |
| Novo Nordisk INC | $153.23 | 2020-2025 | Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $110.70 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $108.36 | 2021 | |
| Ironwood Pharmaceuticals, INC | $107.61 | 2020-2023 | Linzess |
| Novartis Pharmaceuticals Corporation | $98.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $67.86 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $49.28 | 2020-2021 | |
| Allergan, INC. | $44.31 | 2019-2020 | |
| Biogen, INC. | $43.56 | 2021-2022 | |
| Shield Therapeutics INC | $40.51 | 2023-2024 | Accrufer |
| Esperion Therapeutics, INC. | $37.26 | 2020-2021 | |
| Hologic Sales and Service, LLC | $31.94 | 2019-2020 | |
| Daiichi Sankyo INC. | $31.62 | 2019-2021 | |
| Exact Sciences Corporation | $25.60 | 2025 | Cologuard Collection Kit |
| Redhill Biopharma INC. | $21.60 | 2020 | |
| Abbott Laboratories | $18.83 | 2023 | Freestyle Libre 2 |
| Otsuka America Pharmaceutical, INC. | $18.31 | 2025 | Rexulti |
| Genmab U.S., INC. | $16.98 | 2025 | Epkinly |
| Mylan Specialty L.P. | $16.42 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $16.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parminder Janda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.